Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/ebxhCfbwoceVgKbtOzUN

December 7, 2012
Sign upForwardArchiveAdvertiseRead more at SmartBrief.com
News for nuclear medicine and molecular imaging professionals
 
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at snmmi@smartbrief.com.

  Top Story 
  • NRG delays restart of High Flux Reactor
    Nuclear Research and Consultancy Group in the Netherlands said it is pushing back the restart of its High Flux Reactor following the detection of a problem in the reactor's cooling water system. NRG did not give a date for a possible resumption of operations, but said "all efforts are being made to maintain continuity in the production of medical isotopes in an optimal way." NRG said it may be able to give an update by the middle of the month. In other news, Covidien unit Mallinckrodt said it will still be able to meet the demand for isotopes in the following weeks. AuntMinnie.com (free registration) (12/6) LinkedInFacebookTwitterEmail this Story
  • Polish reactor steps up isotope production efforts:   The MARIA research reactor in Poland has increased isotope production efforts following the shutdown of the research reactor in Petten, the Netherlands. The reactor conducted additional irradiation sessions to produce extra molybdenum-99 that could allow for 300,000 more medical tests. Operators of the reactor said this was one way of addressing a gap in the nuclear medicine preparation market resulting from the closure. PhysOrg.com/News release (12/6) LinkedInFacebookTwitterEmail this Story
  Clinical News & Research 
  • Sirtex, SingHealth to explore nanoparticles in treating cancer
    Sirtex Medical and SingHealth have entered a deal to develop the use of carbon-cage nanoparticles in treating cancer. The technology is based on Technegas, which is used in nuclear medicine as an inhalable aerosol of carbon-cage nanoparticles for detecting blood clots in the lungs. The first research initiative under the partnership will explore the technology as a treatment for advanced ovarian cancer that has metastasized in the abdomen and pelvic region. Genetic Engineering & Biotechnology News (12/6) LinkedInFacebookTwitterEmail this Story
  Industry Report 
  • CoreLab unveils imaging system for Alzheimer's diagnosis
    CoreLab Partners has introduced an imaging service designed for use of an independent central image review system for the diagnosis of early Alzheimer's disease. Michael Woehler, CoreLab's president and CEO, said the company plans to establish a team of health care providers equipped with the proper tools for improved evaluation of images from various advanced modalities, including PET and SPECT. AuntMinnie.com (free registration) (12/6) LinkedInFacebookTwitterEmail this Story
  • Bruker enables Innova-IRIS with TERS probes
    Bruker has launched a line of tip-enhanced Raman spectroscopy agents for use with its Innova-Integrated AFM-Raman Imaging System. The development allows for the identification of chemicals at the nanoscale with high sensitivity and spacial resolution, the company said. TMWorld.com/News release (12/4) LinkedInFacebookTwitterEmail this Story
  News from the Field 
  • NIDA shifts focus of grants to translational, genetic medicine
    The National Institute on Drug Abuse has restructured its small business technology transfer and small business innovation research grant programs, which make up for roughly 2.8% of its annual budget, to focus on projects that aim to discover substance abuse treatments using translational and genetic medicine. "We're interested in areas of genetics, in terms of smoking cessation, pharmacogenomics, treatment of substance abuse, and particularly right now, issues related to prescription substance abuse," said NIDA official Jonathan D. Pollock. The NIH unit is also interested in supporting development and commercialization of biomarkers, stem cell reagents, genomic and proteomic data and related technologies. Genetic Engineering & Biotechnology News (12/6) LinkedInFacebookTwitterEmail this Story
  Health Policy 
  • FDA approves more drugs this year
    The FDA has approved 31 new drugs in 2012 for conditions including cancer, HIV, multiple sclerosis and rheumatoid arthritis. The total is the most since 2004, reflecting faster drug development. A separate report showed that in fiscal year 2012 the agency granted 35 new approvals. The Wall Street Journal (12/5) LinkedInFacebookTwitterEmail this Story
  • AdvaMed urges repeal of device tax regardless of IRS final rule
    AdvaMed has stepped up calls for a repeal of the 2.3% medical device tax in light of a final rule released Wednesday by the IRS. AdvaMed President Stephen Ubl said his group is carefully evaluating the final rule, but he sounded alarm over a potential "innovation cliff," loss of about 43,000 jobs and other repercussions if the tax is allowed to take effect next month. MassDevice.com (Boston) (12/5) LinkedInFacebookTwitterEmail this Story
  Advancing Health Care 
  • Agencies issue proposed changes to MU criteria
    The CMS and the Office of the National Coordinator for Health IT have released a proposed rule that makes some changes to meaningful use criteria, including an alternative criterion regarding electronic transmission of structured lab data between hospitals and centers for ambulatory care. The proposed rule also included a change to the 2014 EHR certification criteria. Modern Healthcare (subscription required) (12/5) LinkedInFacebookTwitterEmail this Story
  From SNMMI 
  • Submit an abstract for the SNMMI 2013 Annual Meeting
    Abstracts are currently being accepted for the SNMMI 2013 Annual Meeting, June 8-12, 2013, in Vancouver, British Columbia. Submit an abstract on the following topics: neurosciences, general clinical specialties, molecular targeting probes -- radioactive and nonradioactive, instrumentation and data analysis, oncology: basic, translational and therapy, and oncology: clinical diagnosis. Submission deadline is Jan. 4, 2013. LinkedInFacebookTwitterEmail this Story
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

  SmartQuote 
You will never find time for anything. If you want time you must make it."
--Charles Buxton,
British brewer, philanthropist, writer and legislator


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
   
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Advertise
Account Director:   Meryl Harold   (202) 407-7828
 
Read more at SmartBrief.com
 
 
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.®  Legal Information